Investigational drug · Phase 2
R3R01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "R3R01"
First trial start
2022
Jun 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "R3R01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Kidney Disease
- Alport Syndrome
- Focal Segmental Glomerulosclerosis
Approved drugs for the same conditions: Cardiovascular and metabolic · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "R3R01" as an intervention, largest first.
River 3 Renal Corp.Industry
NCT06600412 · 60 participants (planned) · Start Oct 10, 2024 · Primary completion Apr 1, 2027
Drug: R3R01; Placebo · For: Diabetic Kidney Disease
Sites: Copenhagen, Denmark
River 3 Renal Corp.Industry
NCT05267262 · 43 participants · Start Jun 15, 2022 · Primary completion May 21, 2025
Drug: R3R01 · For: Alport Syndrome; Focal Segmental Glomerulosclerosis
Sites: Los Angeles, California; Boca Raton, Florida; Miami, Florida · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome.
Lo Re C, Kim JJ, Fornoni A · Pediatr Nephrol 2026
- The potential of ARL4C and its-mediated genes in atherosclerosis and agent development.
Liu D, Wang J, Zhang S, et al. · Front Pharmacol 2025
Also in development for Diabetic Kidney Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.